Comprehensive treatment of extensively drug-resistant tuberculosis
- PMID: 18687637
- PMCID: PMC2673722
- DOI: 10.1056/NEJMoa0800106
Comprehensive treatment of extensively drug-resistant tuberculosis
Abstract
Background: Extensively drug-resistant tuberculosis has been reported in 45 countries, including countries with limited resources and a high burden of tuberculosis. We describe the management of extensively drug-resistant tuberculosis and treatment outcomes among patients who were referred for individualized outpatient therapy in Peru.
Methods: A total of 810 patients were referred for free individualized therapy, including drug treatment, resective surgery, adverse-event management, and nutritional and psychosocial support. We tested isolates from 651 patients for extensively drug-resistant tuberculosis and developed regimens that included five or more drugs to which the infecting isolate was not resistant.
Results: Of the 651 patients tested, 48 (7.4%) had extensively drug-resistant tuberculosis; the remaining 603 patients had multidrug-resistant tuberculosis. The patients with extensively drug-resistant tuberculosis had undergone more treatment than the other patients (mean [+/-SD] number of regimens, 4.2+/-1.9 vs. 3.2+/-1.6; P<0.001) and had isolates that were resistant to more drugs (number of drugs, 8.4+/-1.1 vs. 5.3+/-1.5; P<0.001). None of the patients with extensively drug-resistant tuberculosis were coinfected with the human immunodeficiency virus (HIV). Patients with extensively drug-resistant tuberculosis received daily, supervised therapy with an average of 5.3+/-1.3 drugs, including cycloserine, an injectable drug, and a fluoroquinolone. Twenty-nine of these patients (60.4%) completed treatment or were cured, as compared with 400 patients (66.3%) with multidrug-resistant tuberculosis (P=0.36).
Conclusions: Extensively drug-resistant tuberculosis can be cured in HIV-negative patients through outpatient treatment, even in those who have received multiple prior courses of therapy for tuberculosis.
2008 Massachusetts Medical Society
Figures

Comment in
-
Facing extensively drug-resistant tuberculosis--a hope and a challenge.N Engl J Med. 2008 Aug 7;359(6):636-8. doi: 10.1056/NEJMe0804906. N Engl J Med. 2008. PMID: 18687645 No abstract available.
-
Extensively drug-resistant tuberculosis.N Engl J Med. 2008 Nov 27;359(22):2390; author reply 2391. doi: 10.1056/NEJMc081884. N Engl J Med. 2008. PMID: 19038886 No abstract available.
-
Extensively drug-resistant tuberculosis.N Engl J Med. 2008 Nov 27;359(22):2390-1; author reply 2391. N Engl J Med. 2008. PMID: 19051373 No abstract available.
Similar articles
-
Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis.Clin Infect Dis. 2012 Mar;54(6):e51-4. doi: 10.1093/cid/cir904. Epub 2011 Dec 23. Clin Infect Dis. 2012. PMID: 22198790 Free PMC article.
-
Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.Clin Infect Dis. 2008 Aug 15;47(4):496-502. doi: 10.1086/590005. Clin Infect Dis. 2008. PMID: 18611154
-
Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.N Engl J Med. 2003 Jan 9;348(2):119-28. doi: 10.1056/NEJMoa022928. N Engl J Med. 2003. PMID: 12519922
-
[New tuberculosis drugs in resistant and multiresistant tuberculosis].Med Clin (Barc). 2013 Oct 5;141(7):306-13. doi: 10.1016/j.medcli.2013.01.039. Epub 2013 Mar 26. Med Clin (Barc). 2013. PMID: 23540388 Review. Spanish.
-
Management of multidrug resistant tuberculosis.Semin Respir Crit Care Med. 2013 Feb;34(1):44-59. doi: 10.1055/s-0032-1333546. Epub 2013 Mar 4. Semin Respir Crit Care Med. 2013. PMID: 23460005 Review.
Cited by
-
Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality.PLoS One. 2013;8(3):e58664. doi: 10.1371/journal.pone.0058664. Epub 2013 Mar 13. PLoS One. 2013. PMID: 23516529 Free PMC article.
-
Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France.Emerg Infect Dis. 2020 Aug;26(8):1792-1800. doi: 10.3201/eid2608.191499. Emerg Infect Dis. 2020. PMID: 32687026 Free PMC article.
-
Adaptation of a web-based, open source electronic medical record system platform to support a large study of tuberculosis epidemiology.BMC Med Inform Decis Mak. 2012 Nov 7;12:125. doi: 10.1186/1472-6947-12-125. BMC Med Inform Decis Mak. 2012. PMID: 23131180 Free PMC article.
-
Minimal diversity of drug-resistant Mycobacterium tuberculosis strains, South Africa.Emerg Infect Dis. 2014 Mar;20(3):426-33. doi: 10.3201/eid2003.131083. Emerg Infect Dis. 2014. PMID: 24565645 Free PMC article.
-
Multi-drug resistant childhood tuberculosis.Indian J Pediatr. 2011 Apr;78(4):456-63. doi: 10.1007/s12098-010-0344-2. Epub 2010 Dec 31. Indian J Pediatr. 2011. PMID: 21193973 Review.
References
-
- The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Antituberculosis drug resistance in the world: fourth global report. Geneva: World Health Organization; 2008. (Report no. WHO/HTM/TB/2008.394.)
-
- Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(Suppl 2):S231–S279. - PubMed
-
- Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000;283:2537–45. - PubMed
-
- Coninx R, Mathieu C, Debacker M, et al. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet. 1999;353:969–73. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources